BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 19, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Nov. 7, 2012
View Archived Issues
Omeros reports data from second pivotal phase III OMS-302 trial
Read More
Phase III study of BMN-110 meets primary endpoint
Read More
Sanofi and Regeneron begin enrollment in phase III ODYSSEY OUTCOMES trial
Read More
Ventrus Biosciences receives FDA feedback for VEN-307 program
Read More
Significantly elevated IL-8 levels detected in patients with PAP
Read More
Superior model of colorectal cancer devised
Read More
First clinical study of RaQualia's novel 5-HT4 partial agonist completed
Read More
Merck & Co. to initiate phase II trials of MK-5172
Read More
Newron signs amended agreement to acquire NeuroNova
Read More
UCB updates progress of third quarter 2012
Read More
Novel ACAT inhibitors disclosed by Pierre Fabre Medicament
Read More
Antihypercholesterolemic activity of RN-316 confirmed in early clinical studies
Read More
GlaxoSmithKline divulges new mTOR inhibitors
Read More
Dainippon Sumitomo Pharma highlights progress of second quarter of fiscal 2012
Read More
Karo Bio designs novel estrogen receptor-beta ligands
Read More
Biomarkers of acute kidney injury in critical care patients compared
Read More
New beta-secretase inhibitors presented by Roche and Siena Biotech
Read More
New JNK1 inhibitors revealed by Roche
Read More
Spanish group synthesizes new histone deacetylase inhibitors
Read More
Watson completes acquisition of Actavis
Read More
Daiichi Sankyo gives update on activities of second quarter of fiscal 2012
Read More
Long-term clinical remission and mucosal healing demonstrated with golimumab
Read More
Zafgen advances obesity therapy to phase IIa development
Read More
Isotechnika Pharma's NICAMs show antiviral activity in initial screening
Read More
Enrollment completed in phase III study of custirsen in advanced prostate cancer
Read More
FDA designates dalbavancin as a QIDP
Read More